Identifying the source of peritoneal carcinomatosis by molecular biological method (a clinical case) [PDF]
РМЖ. Мать и дитя, 2023 K.R. Ishmuratova1,2 1Bashkir State Medical University, Ufa, Russian Federation 2Republican Clinical Oncological Dispensary, Ufa, Russian Federation In recent decades, multiple biological markers have been discovered which demonstrate a high ...
K.R. Ishmuratova
doaj
Journal for ImmunoTherapy of Cancer, 2020 Background Peritoneal carcinomatosis is a hallmark of advanced peritoneal tumor progression, particularly for tubal/ovarian high-grade serous carcinomas (HGSCs).
Chien-Fu Hung +7 more
doaj +1 more source
Exploring the HYDRAtion method for loading siRNA on liposomes : the interplay between stability and biological activity in human undiluted ascites fluid [PDF]
, 2016 Delivery of small interfering RNA (siRNA) is recently gaining tremendous attention for the treatment of ovarian cancer. The present study investigated the potential of different liposomal formulations composed of (2,3-dioleoyloxy-propyl)trimethylammonium
Braeckmans, Kevin +4 more
core +2 more sources
Peritoneal Tuberculosis Mimicking Peritoneal Carcinomatosis
Medical Journal of Zambia, 2018 Tuberculosis is a serious infection that can appear in many forms and presentations. Here, we highlight a case of a 13 year old patient with a three-month history of nonspecific abdominal pain whose symptoms persisted after treating Typhoid and H. pylori infections.
Martynov, A +4 more
openaire +2 more sources
The Korean Journal of Gastroenterology, 2018 Background/Aims: Diagnostic tests for carcinoembryonic antigen (CEA) in ascites have been performed in various malignant cases, but there is only few data on the applicability of CEA for colorectal cancer (CRC) patients with peritoneal carcinomatosis. We
Sung Eun Song +7 more
doaj +1 more source
Disregarded effect of biological fluids in siRNA delivery : human ascites fluid severely restricts cellular uptake of nanoparticles [PDF]
, 2015 Small interfering RNA (siRNA) offers a great potential for the treatment of various diseases and disorders. Nevertheless, inefficient in vivo siRNA delivery hampers its translation into the clinic.
Braeckmans, Kevin +5 more
core +2 more sources
Diagnostics, 2023 It is challenging to differentiate between tuberculous peritonitis and peritoneal carcinomatosis due to their insidious nature and intersecting symptoms. Computed tomography (CT) is the modality of choice in evaluating diffuse peritoneal disease.
Daya K. Jha +8 more
doaj +1 more source
Establishment and identification of a rabbit model of peritoneal carcinomatosis from gastric cancer
BMC Cancer, 2010 Background Gastric cancer peritoneal carcinomatosis is a common clinical problem, but there are no suitable large animal models to study this problem. This study was to establish a stable rabbit peritoneal carcinomatosis model of gastric cancer using VX2
Yonemura Yutaka +5 more
doaj +1 more source
EGFR inhibitor as second-line therapy in a patient with mutant RAS metastatic colorectal cancer: circulating tumor DNA to personalize treatment [PDF]
, 2018 A 47-year-old male patient presented in March 2016 to our unit with a palpable painless left supraclavicular mass. A whole-body contrastenhanced computed tomography (CT) scan revealed a left supraclavicular lymphadenopathy, transverse colon thickening ...
Cortesi, Enrico +3 more
core +1 more source
Targeting the tumor microenvironment in colorectal peritoneal metastases
, 2020 Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (
Ceelen, Wim +4 more
core +1 more source